ANGLE has a 65% holding in NeuroTargets. ANGLE’s investment in the business at present is minimal and development of the business is being maintained by the Chief Scientific Officer and Founder, Professor David Wynick of the University of Bristol.
NeuroTargets has had positive pre-clinical results for the treatment of multiple sclerosis (MS) and Alzheimer’s disease (AD). NeuroTargets has secured a granted patent in Australia for the use of galanin to treat MS and AD and applications in other territories are ongoing. NeuroTargets has long term potential that requires partnering. Whilst ANGLE is not currently providing any significant investment, Professor Wynick is working with the Medical Research Council seeking to progress these opportunities.
NeuroTargets intellectual property has also recently been the subject of a publication in the PNAS Scientific Journal which identifies the relevance of galanin to Multiple Sclerosis. Professor Wynick and the University of Bristol are currently seeking GAL-R2 targets for further investigation.